Read the latest press releases from Calliditas Therapeutics by clicking on a title below.

For press enquiries please contact us.

Number of shares and votes in Calliditas Therapeutics

European Commission approves Kinpeygo® for adults with primary IgA nephropathy

Calliditas announces additions to the management team

Number of shares and votes in Calliditas Therapeutics

Calliditas Therapeutics establishes a U.S. At-the-Market Program

Issuance and repurchase of C-shares to establish an at-the-market program

Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)

Calliditas receives positive CHMP opinion in IgA nephropathy

Interim Report Q1, 2022

First patient randomized in Phase 2 trial in head and neck cancer

Calliditas Therapeutics to participate in upcoming investor conferences

Number of shares and votes in Calliditas Therapeutics

Calliditas Therapeutics’ 2021 Annual Report Published

Notice of annual general meeting of Calliditas Therapeutics AB (publ)

Calliditas CEO acquires shares through the exercise of Calliditas’ warrant program 2018/2022

Calliditas provides a regulatory update on EMA process for Nefecon

Updated regulatory plans for NEFECON in China

Expansion of Everest Medicine’s licence agreement to include South Korea

Year-End Report, 2021

First patient randomized in pivotal TRANSFORM study with setanaxib

Calliditas Therapeutics Announces Commercial Availability and Initial Sales of TARPEYO™